Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 35, 2018 - Issue 7-8
Submit an article Journal homepage
256
Views
17
CrossRef citations to date
0
Altmetric
Articles

Outcome of children with Langerhans cell histiocytosis and single-system involvement: A retrospective study at a single center in Shanghai, China

Meng SuKey Laboratory of Pediatric Hematology & Oncology, Department of Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaORCID Iconhttp://orcid.org/0000-0001-5888-2788
ORCID Icon,
Yi-Jin GaoKey Laboratory of Pediatric Hematology & Oncology, Department of Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaCorrespondence[email protected]
,
Ci PanKey Laboratory of Pediatric Hematology & Oncology, Department of Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
,
Jing ChenKey Laboratory of Pediatric Hematology & Oncology, Department of Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
&
Jing-Yan TangKey Laboratory of Pediatric Hematology & Oncology, Department of Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Pages 385-392 | Received 21 Mar 2018, Accepted 27 Sep 2018, Published online: 29 Jan 2019

References

  • Minkov M. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Paediatr Drugs. 2011;13:75–86.
  • Vaiselbuh SR, Bryceson YT, Allen CE, Whitlock JA, Abla O. Updates on histiocytic disorders. Pediatr Blood Cancer. 2014;61(7):1329–1335.
  • Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 2001;138(5):728–734.
  • Gadner H, Grois N, Pötschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008;111(5):2556–2562.
  • Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood 2013;121(25):5006–5014.
  • Morimoto A, Ikushima S, Kinugawa N, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer 2006;107(3):613–619.
  • Morimoto A, Shioda Y, Imamura T, et al. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol. 2016;104(1):99–109.
  • Chellapandian D, Shaikh F, van den Bos C, et al. Management and outcome of patients with Langerhans cell histiocytosis and single‐bone CNS‐risk lesions: a multi‐institutional retrospective study. Pediatr Blood Cancer. 2015;62(12):2162–2166.
  • Gadner H, Heitger A, Grois N, Gatterer-Menz I, Ladish S. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol. 1994;23(2):72–80.
  • Titgemeyer C, Grois N, Minkov M, et al. Pattern and course of single‐system disease in Langerhans cell histiocytosis data from the DAL-HX 83‐and 90‐study. Med Pediatr Oncol. 2001;37:108–114.
  • Carstensen H, Ornvold K. The epidemiology of Langerhans cell histiocytosis in children in Denmark. Med Pediatr Oncol. 1993;21:387–388.
  • Imashuku S, Ikushima S, Hibi S, et al. Langerhans cell histiocytosis and hemophagocytic syndrome in Japan; epidemiological studies. Int J Hematol Oncol. 1994;1:241–246.
  • Alston RD, Tatevossian RG, McNally RJ, Kelsey A, Birch JM, Eden TO. Incidence and survival of childhood Langerhans cell histiocytosis in Northwest England from 1954 to 1998. Pediatr Blood Cancer. 2007;48(5):555–560.
  • Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004. Pediatr Blood Cancer. 2008;51(1):71–75.
  • Salotti JA, Nanduri V, Pearce MS, Parker L, Lynn R, Windebank KP. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child. 2009;94(5):376–380.
  • Gao YJ, Su M, Tang JY, Pan C, Chen J. Treatment outcome of children with myltisystem Langerhans Cell Histiocytosis: the experience of a single children’s hospital in Shanghai, China. J Pediatr Hematol Oncol. 2018;40:e9–e12.
  • Arico M. Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy. Br J Haematol. 2016;173:663–670.
  • Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004;42(5):438–444.
  • Chow TW, Leung WK, Cheng FWT, et al. Late outcomes in children with Langerhans cell histiocytosis. Arch Dis Child. 2017;102(9):830–835.
  • Haupt R, Minkov M, Astigarraga I, et al. Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013;60(2):175–184.
  • Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211(4):669–683.
  • Allen CE, Ladisch S, McClain KL. How I treat Langerhans cell histiocytosis. Blood 2015;126(1):26–35.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.